Xenetic Biosciences reports Q2 net loss of $2.7M; advances DNase platform toward Phase 1 study

Xenetic Biosciences, Inc.

2022-Q2 EPS reported -$0.31 revenue$805,703

Net loss of approx $2.7M for Q2 2022; R&D expense rose 296% to $2.1M, including $1.3M IPR&D for DNase license.
Cash balance of $14.9M at quarter end; royalty payments from Takeda sublicensee ~$0.4M (+45% YoY).
In-licensed DNase-based oncology platform from CLS Therapeutics in April 2022; targeting Phase 1 in pancreatic carcinoma.
Engaged Catalent for cGMP manufacturing of Phase 1 clinical supply; collaboration with Belgian Volition for NETs-targeted cell therapies.
Bolstered IP with U.S. patent for XCART platform covering co-administration of CAR T cells with personalized vaccine.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.